Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00067782 · ClinicalTrials.gov registry record · Phase 3
A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00067782: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT00067782 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00067782, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
The purpose of this clinical research study is to learn if atazanavir is associated with serum LDL cholesterol in HIV-infected subjects following a substitution of atazanavir for their previously administered protease inhibitor.
Interventions
- DRUG Atazanavir (immediate switch)
- DRUG Atazanavir (Week 24 switch)
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-12 |
| Est. Completion | 2005-03 |
| Phase | Phase 3 |
What the finished NCT00067782 record still lists
NCT00067782 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which Atazanavir (immediate switch) is the first listed.
NCT00067782 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00067782 about?
NCT00067782 is a clinical study titled "A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy". The purpose of this clinical research study is to learn if atazanavir is associated with serum LDL cholesterol in HIV-infected subjects following a substitution of atazanavir for their previously administered protease inhibitor.
What is the current status of trial NCT00067782?
This trial is currently completed. It is a Phase 3 study. The study started on 2002-12. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00067782?
The interventions under investigation include: Atazanavir (immediate switch) (DRUG), Atazanavir (Week 24 switch) (DRUG).
Who is sponsoring clinical trial NCT00067782?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia